Liver Forum 18 was held in Reston, VA on Friday, April 4 - Saturday, April 5, 2025

Materials

Agenda

Participant List

Session I: Welcome and Introductory Remarks

Welcome & Forum Overview
Edyth Dwyer & Sehyr Khan, Forum
Introductory Remarks
Michelle Long, Novo Nordisk
Veronica Miller, Forum
Arun Sanyal, VCU

Session II: PEDDLE Working Group Update & Toolkit Proposal

PEDDLE Forward: Driving Patient-Centered Innovation in MASH Drug Development
Michael Betel, Fatty Liver Alliance
From Ideas to Impact: Our Patient Engagement Journey So Far
Rosemarie Sellati, Regeneron Pharmaceuticals
Moving Forward: Building the Toolkit for Engagement
Henry Chang, Fatty Liver Foundation

Session III: Forum NITs for RLSE Proposal- Focus on Fibrogenesis

Discussion Framework of Liver Forum Proposal for a New NIT-based RLSE in MASLD
Quentin Anstee, Newcastle University

Session IV: Data & Analysis Review

FCR NIT Literature Review
Richard Haubrich, Forum
Unicorn Biomarkers
Morten Karsdal, Nordic Bioscience*
Moving ELF closer to a Reasonably Likely Surrogate Endpoint
Matthew Gee, Siemens Healthineers
LSM by VCTE as a Reasonably Likely Surrogate Endpoint: Review of the Latest Clinical Evidence
Céline Fournier, Echosens
Insights into NIT CV from the Pfizer MIRNA Trial
Quentin Anstee, Newcastle University
Exploratory analysis: ELF components in 4296 and 4492
Michelle Long, Novo Nordisk
Non-Invasive Tests for Reasonably- Likely Surrogate Endpoints: MRE
Kay Pepin, Resoundant*

Session V: Consideration of Non-Fibrogenic Biomarkers

cT1 as a Reasonably Likely Surrogate Endpoint in MASH Clinical Trials
Rajarshi Banerjee & Andrea Dennis, Perspectum

Session VI: Coming to Consensus on NITs for an RLSE

What is Meaningful to the Patients?
Henry Chang, Fatty Liver Foundation

Session VII: Future of NITs & Day Wrap Up

Day Wrap Up
Michelle Long, Novo Nordisk
Veronica Miller, Forum
Arun Sanyal, VCU

Session VIII: Stretch Exercise in Statistics

Beyond Binary Outcomes
Michael Harhay, University of Pennsylvania*

Session IX: Defining Progression to Cirrhosis

Progression to Cirrhosis– Considerations in Operationalizing the Endpoint
Arun Sanyal, VCU
MAESTRO-NASH Outcomes: Identification of F4 without Biopsy
Becky Taub, Madrigal Pharmaceuticals

Session X: Closing Remarks

Closing Remarks
Michelle Long, Novo Nordisk
Veronica Miller, Forum
Arun Sanyal, VCU

 

*Remote participation